Bruker (BRKR) AI Stock Analysis

• Market Cap: $6.13B
• Dividend Yield: 0.51%
• Average Volume (3M): 3.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.17
• Revenue Growth: 6.10%
• EPS Growth: -107.47%
• Country: US
• Employees: 11,396
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.45
• Shares Outstanding: 151,719,360
• 10 Day Avg. Volume: 3,432,242
• 30 Day Avg. Volume: 3,810,824
• PEG Ratio: -1.04
• Price to Book (P/B): 4.90
• Price to Sales (P/S): 2.59
• P/FCF Ratio: 64.22
• Enterprise Value/Market Cap: 1.41
• Enterprise Value/Revenue: 2.52
• Enterprise Value/Gross Profit: 5.32
• Enterprise Value/Ebitda: 29.99
• 1Y Price Target: $47.17
• Price Target Upside: 8.71% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $42.00 ▼(-3.20% Downside)

Bruker's overall stock score reflects challenges in financial performance, particularly in revenue growth and cash flow management. While technical indicators show positive momentum, the high P/E ratio suggests potential overvaluation. The earnings call highlighted both improvements and ongoing challenges, with expectations for future growth.

Positive Factors

Innovative Product Launches

New product launches in spatial biology and proteomics enhance Bruker's leadership in drug discovery tools, supporting long-term growth.

Cost Savings Initiatives

Successful cost-saving measures are expected to expand margins and drive EPS growth, strengthening financial performance over time.

Order Performance Improvement

Improved order performance, with a book-to-bill ratio over 1.0, indicates strong demand and potential revenue growth in upcoming periods.

Negative Factors

Revenue Decline

A decline in revenue reflects challenges in market demand, potentially affecting long-term growth and financial stability.

Operational and Margin Challenges

Decreased margins due to operational inefficiencies may hinder profitability and require strategic adjustments to improve performance.

Cash Flow Weakness

Weak cash flow generation limits financial flexibility and may impact the company's ability to invest in growth opportunities.

Bruker Business Overview & Revenue Model

Company Description

Bruker Corporation (BRKR) is a global leader in scientific instrumentation and analytical solutions, primarily serving the life sciences, materials science, and industrial markets. The company specializes in the development and production of advanced technologies, including mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, X-ray diffraction, and optical microscopy. With a strong emphasis on innovation, Bruker delivers high-performance instruments and integrated solutions that enable researchers and scientists to gain insights into complex biological and material properties.

How the Company Makes Money

Bruker generates revenue through multiple streams, primarily from the sale of its scientific instruments and related services. The company markets its products to a diverse range of sectors, including academic research, pharmaceuticals, biotechnology, and environmental testing. Key revenue streams include instrument sales, service contracts, and consumables that support ongoing operations of the instruments. Additionally, Bruker benefits from partnerships and collaborations with research institutions and pharmaceutical companies, which can lead to increased sales and joint development opportunities. The company's focus on innovation and expanding its product portfolio, along with a strong customer base, contributes significantly to its earnings.

Bruker Financial Statement Overview

Summary

Bruker faces challenges in revenue growth and cash flow generation, with declining profitability margins. The income statement shows a decline in revenue growth rate and decreased EBIT and EBITDA margins. The balance sheet is stable but with a slightly high debt-to-equity ratio. Cash flow issues are evident with negative free cash flow and low operating cash flow to net income ratio.

Income Statement

Bruker's income statement shows a mixed performance. The TTM data indicates a decline in revenue growth rate at -11.3%, which is concerning. However, the company maintains a reasonable gross profit margin of 48% and a net profit margin of 2.31%. The EBIT and EBITDA margins have decreased compared to previous years, indicating potential challenges in operational efficiency.

Balance Sheet

The balance sheet reflects a stable financial position with a debt-to-equity ratio of 1.34, which is slightly high but manageable. The return on equity has decreased to 4.4% in the TTM, suggesting reduced profitability. However, the equity ratio remains healthy, indicating a solid asset base.

Cash Flow

The cash flow statement reveals some weaknesses, particularly in free cash flow, which has turned negative in the TTM. The operating cash flow to net income ratio is low at 0.12, indicating potential liquidity issues. The free cash flow to net income ratio is 0.30, showing limited cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.44B	3.37B	2.96B	2.53B	2.42B	1.99B
Gross Profit	1.63B	1.65B	1.51B	1.31B	1.21B	939.80M
EBITDA	288.60M	438.60M	675.50M	518.70M	497.10M	320.60M
Net Income	-20.90M	113.10M	427.20M	296.60M	277.10M	157.80M
Balance Sheet
Total Assets	6.43B	5.81B	4.25B	3.61B	3.65B	3.05B
Cash, Cash Equivalents and Short-Term Investments	295.00M	183.40M	488.30M	645.50M	1.17B	731.80M
Total Debt	2.05B	2.25B	1.38B	1.27B	1.39B	912.80M
Total Liabilities	3.94B	3.99B	2.84B	2.48B	2.57B	2.07B
Stockholders Equity	2.43B	1.78B	1.38B	1.11B	1.07B	961.20M
Cash Flow
Free Cash Flow	-10.60M	136.00M	243.20M	145.20M	190.40M	235.00M
Operating Cash Flow	94.30M	251.30M	350.10M	274.40M	282.40M	332.20M
Investing Cash Flow	-201.60M	-1.76B	-326.00M	-251.60M	-192.40M	-192.70M
Financing Cash Flow	227.70M	1.23B	-193.40M	-415.30M	318.70M	-161.60M

Bruker Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 43.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRKR, the sentiment is Positive. The current price of 43.39 is above the 20-day moving average (MA) of 40.40, above the 50-day MA of 36.98, and above the 200-day MA of 39.32, indicating a bullish trend. The MACD of 1.72 indicates Negative momentum. The RSI at 69.92 is Neutral, neither overbought nor oversold. The STOCH value of 82.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BRKR.

Bruker Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GMED	82 Outperform	$13.10B	27.09	10.01%	―	11.75%	364.73%
BRKR	64 Neutral	$6.13B	-258.35	4.43%	0.51%	6.10%	-107.47%
ITGR	61 Neutral	$2.37B	28.33	5.18%	―	7.81%	-26.32%
BIO	58 Neutral	$8.23B	-12.49	-9.50%	―	-0.88%	10.93%
LIVN	58 Neutral	$2.94B	―	-17.63%	―	8.97%	-1024.86%
GKOS	52 Neutral	$5.54B	―	-12.19%	―	30.38%	47.64%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bruker Corporate Events

Bruker Corporation Reports Q3 2025 Financial Results

Bruker Corporation is a leader in the scientific instruments sector, providing high-performance analytical and diagnostic solutions for life sciences, applied and industrial markets. The company recently reported its third-quarter financial results for 2025, showing a slight decline in revenue compared to the previous year, with total revenues of $860.5 million, down 0.5% year-over-year. Despite a challenging market environment, Bruker saw positive growth in its bookings, particularly in the academic and biopharma sectors, driven by new product launches in spatial biology and proteomics.

Bruker Raises $669.5 Million Through Underwriting Agreement

On September 3, 2025, Bruker entered into an underwriting agreement with J.P. Morgan Securities LLC and BofA Securities, Inc. for an offering. The company raised approximately $669.5 million in net proceeds after deducting underwriting discounts and estimated offering expenses.

The most recent analyst rating on (BRKR) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Bruker stock, see the BRKR Stock Forecast page.

Bruker Corporation Faces Challenges Amid Revenue Decline

Bruker Corporation’s recent earnings call highlighted a challenging quarter marked by significant revenue declines and reduced guidance. The company faced headwinds from market conditions, tariffs, and foreign exchange fluctuations. Despite these hurdles, Bruker is taking proactive steps with cost-saving measures and continues to innovate, particularly in diagnostics and new product launches. However, the negative aspects, such as revenue and EPS declines, along with challenges in U.S. academic funding, overshadow the positives.

Bruker Corporation Reports Q2 2025 Financial Results

Bruker Corporation is a leading company in the life sciences sector, specializing in high-performance scientific instruments and analytical solutions that enable breakthroughs in post-genomic discoveries and applications. The company operates across various segments, including life science research, applied and biopharma applications, and industrial research.